Literature DB >> 25841505

Advances in loco-regional palliation of unresectable cholangiocarcinomas.

Sanem Guler1, Sertac Cimen1, Michele Molinari2.   

Abstract

Cholangiocarcinoma (CC) represents the second most common primary hepatic malignancy after hepatocellular carcinoma, accounting for 10% to 15% of primary liver tumors. Its prognosis is often poor due to its late presentation and its relative resistance to current chemotherapy and radiotherapy regimens. At the time of diagnosis, more than half of the patients are not candidates for surgical therapy due to either invasion of vascular structures or distant metastases. Therefore, for a large proportion of patients, palliation remains the only option for better quality of life and, in some circumstances, longer survival. The main goals of palliative interventions for CC are: restoration of the biliary drainage and resolution of pruritis caused by obstructive jaundice, improvement of the nutritional status and reduction of pain. During the last decades, novel therapies have been introduced to optimize the management of patients with unresectable CC. These therapies can be resource intensive and have some adverse effects; therefore patient selection is crucial. This article discusses the current options for palliation of CC.

Entities:  

Keywords:  Palliation; cholangiocarcinoma (CC); locoregional therapy

Year:  2014        PMID: 25841505     DOI: 10.3978/j.issn.2224-5820.2014.03.01

Source DB:  PubMed          Journal:  Ann Palliat Med        ISSN: 2224-5820


  3 in total

Review 1.  Malignant biliary obstruction: From palliation to treatment.

Authors:  Brian R Boulay; Aleksandr Birg
Journal:  World J Gastrointest Oncol       Date:  2016-06-15

2.  Locoregional therapies in cholangiocarcinoma.

Authors:  Peter L Labib; Brian R Davidson; Ricky A Sharma; Stephen P Pereira
Journal:  Hepat Oncol       Date:  2017-11-17

3.  Development of a methodology for in vivo follow-up of hepatocellular carcinoma in hepatocyte specific Trim24-null mice treated with myo-inositol trispyrophosphate.

Authors:  Mihaela Ignat; Cherif Youssef Akladios; Véronique Lindner; Konstantin Khetchoumian; Marius Teletin; Didier Muttter; Pierre Marc Aprahamian; Jacques Marescaux
Journal:  J Exp Clin Cancer Res       Date:  2016-09-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.